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Over the last 2 yr, there has been an unprecedented wealth of randomised controlled trials 
(RCTs) illuminating outcomes in localised prostate cancer (PCa). Several thousand patients 
have been included, spanning low-risk to advanced localised disease. The ProtecT trial [1] is 
the only substantial study comparing management options in screen-detected, predominantly 
low-risk disease. Favourable 10-yr survival was demonstrated whether using active 
monitoring, prostatectomy, or conventionally fractionated external-beam radiotherapy 
(EBRT) with a short course of androgen deprivation therapy (ADT). The excess risk of 
metastasis developing in the active monitoring group is a concern but may be mitigated by 
improvements in the surveillance pathway using, for example, magnetic resonance imaging 
(MRI) to identify disease progression, and by exploration of biomarkers to better select 
patients. The ProtecT study also gives important information on patient-reported outcomes; 
no intervention can be distinguished on overall health-related quality of life, but unbiased 
observers may note some advantage for nonsurgical intervention. In a second group of 
studies, more than 5000 patients have been included in radiotherapy (RT) studies of modest 
hypofractionation [2]. The patients included had predominantly intermediate- or high-risk 
disease. Treatment using fractions of 3 Gy/d to a total dose of 60 Gy over 4 wk was as 
effective and with similar late side effects as conventional 2-Gy daily fractions delivered to 
doses of 74–78 Gy, whether or not short-course ADT was used. Very importantly, treatment 
techniques using intensity-modulated RT (IMRT), with or without image guidance (IGRT) 
and with mandated normal tissue dose constraints, have reduced gastrointestinal side effects 
by approximately 50%. The shorter schedule is expected to become the new standard of care, 
with considerable benefits in terms of patient convenience and use of health care resources. 
Results of more extreme (eg, 5 fractions) hypofractionation studies in Sweden (HYPRO trial 
ISRCTN85138529) and UK/Canada (PACE ISRCTN17627211) are awaited. 
The improved outcome using ADT observed in the CHHiP trial (with ADT) compared to the 
PROFIT study (without ADT)
  
mirrors the advantage shown for ADT in the recent EORTC 
trial report [3] using high-dose EBRT. It appears that short-course ADT impacts on micro-
metastases as well as local tumour control. The results of “super-ADT” have just been 
reported for the Medical Research Council STAMPEDE trial. Standard of care (SOC) in 
patients with locally advanced or metastatic prostate cancer was compared with SOC plus 
abiraterone acetate and prednisolone (AAP) [4]. An overall survival advantage was shown, 
but, very strikingly, the hazard ratio (HR) for failure-free survival, was 0.29 (p < 0.4  10−61) 
in favour of SOC + AAP, with an even lower HR of 0.21 in the M0 group. This will probably 
translate into a long-term survival advantage and opens up a new era in the successful 
treatment of advanced, high-grade localised disease. 
*Manuscript
Despite these large trials and their practice-changing results, we remain left with the 
quandary of which patients are best treated with primary surgical or RT options. In this issue 
of European Urology, Wallis and colleagues [5] address this issue in their international 
review of surgery or RT. They appropriately conclude that we just do not have the evidence 
from RCTs to reach a sound judgement. They comment that it has been shown that surgery 
prolongs survival compared to watchful waiting in clinically localised disease in the SPCG-4 
trial, at least for younger age groups. The firming up of this conclusion with >10-yr long-term 
follow-up is instructive. However, there has been no similar RT RCT for this group. 
Similarly, RT with long-course ADT prolongs survival in advanced localised disease [6,7], 
but there are no surgical RCTs in this group. The key issue to appreciate is that both local 
modalities produce good efficacy, and differences in survival outcomes are likely to be small 
at most. It is questionable whether large enough phase 3 trials will be ever be performed in 
appropriate patient subgroups. Therefore, the temptation is to turn to observational data. As 
Wallis et al [5] point out in their review, such data are confounded by both known and 
unknown variables. Statistical tools attempt to correct the known imbalances; propensity 
score analysis is frequently used. However, it is salutary to note that it has been shown that 
these techniques are ineffective in localised PCa [8] and we believe the resulting comparative 
data are flawed and certainly unsuitable for making decisions on health care delivery. 
Globally, it has been reported that PCa is the major cause of “years lived with disability” 
among men [9]. This emphasises the importance of reducing treatment-related effects as far 
as possible. Treatment should be avoided when not needed, and focal therapies need to be 
studied and their efficacy and side effect profiles more rigorously assessed. RT techniques 
continue to evolve and improve, with IMRT and IGRT becoming widely available.  Focal 
boost treatments directed using high-quality MRI can be given to maximise local control, and 
randomised trials are under way using both standard and moderately hypofractionated 
schedules (FLAME trial NCT01168479, PIVOTALboost CRUK/16/018). ADT should not be 
used unless shown to improve outcome. We need better imaging, tissue, and plasma 
biomarkers to separate patients with intermediate risk into appropriate favourable and 
unfavourable groups, which can then be assessed prospectively to validate biomarker-led 
hypotheses. Which men really need long-course hormone treatment and which subgroups 
would benefit from the addition of “super-ADT” with abiraterone or the new generations of 
potent anti-androgens are relevant questions. 
Another way of looking at the choice between prostatectomy and RT is to ask the question 
“After RT, which patients will develop life-shortening or symptomatic local recurrence?” 
With modern, high-quality RT techniques, the proportion will be small, but prospective 
collection of potentially predictive biomarkers including genetic heterogeneity [10] may be of 
assistance. The use of patient-reported outcomes, particularly using the EPIC instrument, as 
noted by Wallis et al [5], may help us to advise patients of the likely outcomes for different 
treatment modalities. Patient choice after appropriate counselling remains central to decision-
making. We believe that this is best performed in well-functioning, multidisciplinary teams 
that can deliver both high-quality surgery and RT. 
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